Xianhai Mao
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (NCT05111366) | Xianhai Mao | 2022-01-06 |
Track Xianhai Mao automatically
Every clearance here is in the API, with alerts when new ones post.